Clinical outcomes of brain metastasectomy from soft tissue and bone sarcomas: a systematic review.
Brain metastasis
Metastasectomy
Sarcoma
Systematic review
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
14
01
2022
accepted:
31
07
2022
pubmed:
23
8
2022
medline:
29
10
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
Brain metastasis in sarcomas is associated with a poor prognosis. Data regarding prognostic factors and clinical outcomes of surgical resection of brain metastasis from sarcomas are limited. The objective of this systematic review was to evaluate survival outcomes post-brain metastasectomy for patients with soft tissue and bone sarcomas. A systematic review was conducted examining survival outcomes among adults and children with soft tissue and bone sarcoma undergoing brain metastasectomy, in the English language from inception up to May 31, 2021. Two reviewers independently evaluated and screened the literature, extracted the data, and graded the included studies. The body of evidence was evaluated and graded according to the Newcastle-Ottawa Quality Assessment Scale for Cohort Studies and the Joanna Briggs Institute Critical Appraisal Checklist for Case Series. Results were synthesized using descriptive methods. A meta-analysis was not possible due to the low quality and heterogeneity of studies. Ten studies published between 1994 and 2020 were included: three were retrospective cohort studies and seven were case series. 507 patients were included, of whom 269 underwent brain metastasectomy. The median follow-up period ranged between 14 and 29 months. The median survival period after metastasectomy ranged from 7 to 25 months. The most common prognostic factors associated with survival included presenting performance status, age, number of brain metastases, presence of lung metastases, and peri-operative radiation therapy administration. Although the level of evidence is low, retrospective studies support that brain metastasectomy can be performed with reasonable post-operative survival in selected individuals.
Sections du résumé
BACKGROUND
BACKGROUND
Brain metastasis in sarcomas is associated with a poor prognosis. Data regarding prognostic factors and clinical outcomes of surgical resection of brain metastasis from sarcomas are limited. The objective of this systematic review was to evaluate survival outcomes post-brain metastasectomy for patients with soft tissue and bone sarcomas.
METHODS
METHODS
A systematic review was conducted examining survival outcomes among adults and children with soft tissue and bone sarcoma undergoing brain metastasectomy, in the English language from inception up to May 31, 2021. Two reviewers independently evaluated and screened the literature, extracted the data, and graded the included studies. The body of evidence was evaluated and graded according to the Newcastle-Ottawa Quality Assessment Scale for Cohort Studies and the Joanna Briggs Institute Critical Appraisal Checklist for Case Series. Results were synthesized using descriptive methods. A meta-analysis was not possible due to the low quality and heterogeneity of studies.
RESULTS
RESULTS
Ten studies published between 1994 and 2020 were included: three were retrospective cohort studies and seven were case series. 507 patients were included, of whom 269 underwent brain metastasectomy. The median follow-up period ranged between 14 and 29 months. The median survival period after metastasectomy ranged from 7 to 25 months. The most common prognostic factors associated with survival included presenting performance status, age, number of brain metastases, presence of lung metastases, and peri-operative radiation therapy administration.
DISCUSSION
CONCLUSIONS
Although the level of evidence is low, retrospective studies support that brain metastasectomy can be performed with reasonable post-operative survival in selected individuals.
Identifiants
pubmed: 35994183
doi: 10.1007/s10147-022-02227-4
pii: 10.1007/s10147-022-02227-4
doi:
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1767-1779Informations de copyright
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Gamboa AC, Gronchi A, Cardona K (2020) Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin 70(3):200–229
pubmed: 32275330
Novais EN, Demiralp B, Alderete J et al (2010) Do surgical margin and local recurrence influence survival in soft tissue sarcomas? Clin Orthop Relat Res 468(11):3003–3011
pubmed: 20645035
pmcid: 2947688
Kraybill WG, Harris J, Spiro IJ et al (2006) Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 24(4):619–625
pubmed: 16446334
Scurr M, Judson I (2005) Soft-tissue and bone sarcomas. Cancer Chemother Biol Response Modif 22:591–604
pubmed: 16110630
Leong SP, Cady B, Jablons DM et al (2006) Clinical patterns of metastasis. Cancer Metastasis Rev 25(2):221–232
pubmed: 16770534
Bindal RK, Sawaya RE, Leavens ME et al (1994) Sarcoma metastatic to the brain: results of surgical treatment. Neurosurgery 35(2):185–190
pubmed: 7969824
Espat NJ, Bilsky M, Lewis JJ et al (2002) Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients. Cancer 94(10):2706–2711
pubmed: 12173340
Itoga R, Matsuoka M, Onodera T et al (2021) Brain metastasis in soft tissue sarcoma at initial presentation. Anticancer Res 41(11):5611–5616
pubmed: 34732433
Gusho CA, Blank AT, Batus M (2021) Outcomes of brain metastasis in high-grade bone and soft tissue sarcoma: An analysis of clinicopathological characteristics and survival data. Rare Tumors 13:20363613211026150
pubmed: 34221290
pmcid: 8221671
Al Sannaa G, Watson KL, Olar A et al (2016) Sarcoma brain metastases: 28 years of experience at a single institution. Ann Surg Oncol 23(Suppl 5):962–967
pubmed: 27646022
Dasgupta A, Co J, Winter J et al (2021) Clinicopathologic and treatment features of long-term surviving brain metastasis patients. Curr Oncol 28(1):549–559
pubmed: 33477698
pmcid: 7903267
Sperduto PW, Mesko S, Li J et al (2020) Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 38(32):3773–3784
pubmed: 32931399
pmcid: 7655019
Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500
pubmed: 2405271
Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33(6):583–590
pubmed: 8498838
Mintz AH, Kestle J, Rathbone MP et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78(7):1470–1476
pubmed: 8839553
Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060
pubmed: 28687377
pmcid: 5568757
Wang Y, Delisle M, Smith DS et al (2020) Survival by histology among patients with bone and soft tissue sarcoma who undergo metastasectomy: protocol for a systematic review and meta-analysis. Syst Rev 9(1):189
pubmed: 32819423
pmcid: 7441630
Wang Y, Srikanthan A, Smith D et al. (2019) A systematic review and meta-analysis of outcomes of metastasectomy of soft tissue sarcoma by organ
Mathes T, Pieper D (2018) Study design classification of registry-based studies in systematic reviews. J Clin Epidemiol 93:84–87
pubmed: 28951107
Ma LL, Wang YY, Yang ZH et al (2020) Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res 7(1):7
pubmed: 32111253
pmcid: 7049186
Moola S, Munn Z, Tufanaru C et al (2017) Chapter 7: Systematic reviews of etiology and risk. In: Joanna Briggs Institute Reviewer’s Manual. edn. Edited by Aromataris E, Munn Z: The Joanna Briggs Institute
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [ http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp ]
Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13
pubmed: 15840177
pmcid: 1097734
Grossman R, Ram Z (2014) Recursive partitioning analysis (RPA) classification predicts survival in patients with brain metastases from sarcoma. World Neurosurg 82(6):1291–1294
pubmed: 25102368
Borenstein M, Hedges L, Higgins J et al. (2013) Comprehensive Meta Analysis Version 3.0. Englewood, NJ: Biostat
Murad MH, Mustafa RA, Schunemann HJ et al (2017) Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med 22(3):85–87
pubmed: 28320705
pmcid: 5502230
14.2 Assessing the certainty or quality of a body of evidence. In: Cochrane Handbook for Systematic Reviews of Interventions, Version 62. Volume 2021, edn. Edited by Higgins J, Thomas J: The Cochrane Collaboration; 2021.
Wronski M, Arbit E, Burt M et al (1995) Resection of brain metastases from sarcoma. Ann Surg Oncol 2(5):392–399
pubmed: 7496833
Salvati M, D’Elia A, Frati A et al (2010) Sarcoma metastatic to the brain: a series of 35 cases and considerations from 27 years of experience. J Neurooncol 98(3):373–377
pubmed: 20039192
Yoshida S, Morii K, Watanabe M et al (2000) Brain metastasis in patients with sarcoma: an analysis of histological subtypes, clinical characteristics, and outcomes. Surg Neurol 54(2):160–164
pubmed: 11077098
Tao X, Hou Z, Wu Z et al (2017) Brain metastatic alveolar soft-part sarcoma: Clinicopathological profiles, management and outcomes. Oncol Lett 14(5):5779–5784
pubmed: 29113207
pmcid: 5661425
Chaigneau L, Patrikidou A, Ray-Coquard I et al (2018) Brain metastases from adult sarcoma: prognostic factors and impact of treatment. A retrospective analysis from the French Sarcoma Group (GSF/GETO). Oncologist 23(8):948–955
pubmed: 29934413
pmcid: 6156185
Deguchi S, Nakasu Y, Sakaida T et al (2020) Surgical outcome and graded prognostic assessment of patients with brain metastasis from adult sarcoma: multi-institutional retrospective study in Japan. Int J Clin Oncol 25(11):1995–2005
pubmed: 32648133
Fox BD, Patel A, Suki D et al (2009) Surgical management of metastatic sarcoma to the brain. J Neurosurg 110(1):181–186
pubmed: 18834268
Savina M, Le Cesne A, Blay JY et al (2017) Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med 15(1):78
pubmed: 28391775
pmcid: 5385590
Lochner J, Menge F, Vassos N et al (2020) Prognosis of patients with metastatic soft tissue sarcoma: advances in recent years. Oncol Res Treat 43(11):613–619
pubmed: 32854101
Group ESESNW (2014) Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3:102–112
Hellmann MD, Kris MG, Rudin CM (2016) Medians and milestones in describing the path to cancer cures: Telling “Tails.” JAMA Oncol 2(2):167–168
pubmed: 26583516
Ben-Aharon O, Magnezi R, Leshno M et al (2019) Median survival or mean survival: which measure is the most appropriate for patients, physicians, and policymakers? Oncologist 24(11):1469–1478
pubmed: 31320502
pmcid: 6853128
Scurr M (2011) Histology-driven chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol 12(1):32–45
pubmed: 21359911
Rhomberg W (2006) The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxane. Sarcoma 2006(1):87367
pubmed: 17040092
pmcid: 1510952
Ferrat E, Paillaud E, Laurent M et al (2015) Predictors of 1-year mortality in a prospective cohort of elderly patients with cancer. J Gerontol A Biol Sci Med Sci 70(9):1148–1155
pubmed: 25834194
Liuu E, Canoui-Poitrine F, Tournigand C et al (2014) Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study. J Geriatr Oncol 5(1):11–19
pubmed: 24484713
Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35(3):181–200
pubmed: 10960800
Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A et al (2014) Prevalence and prognostic impact of comorbidity in soft tissue sarcoma: a population-based cohort study. Acta Oncol 53(9):1188–1196
pubmed: 24588412
He Y, Li LW, Hao Y et al (2020) Assessment of predictive validity and feasibility of Edmonton Frail Scale in identifying postoperative complications among elderly patients: a prospective observational study. Sci Rep 10(1):14682
pubmed: 32895396
pmcid: 7477578
Owodunni OP, Mostales JC, Qin CX et al (2021) Preoperative frailty assessment, operative severity score, and early postoperative loss of independence in surgical patients age 65 years or older. J Am Coll Surg 232(4):387–395
pubmed: 33385567
Milsch L, Gesierich A, Kreft S et al (2018) Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. Eur J Cancer 99:58–65
pubmed: 29906735
CanSaRCC: Canadian Sarcoma Research and Clinical Collaboration [ https://www.cansarcc.ca ]
Bleloch JS, Ballim RD, Kimani S et al (2017) Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol 9(10):637–659
pubmed: 28974986
pmcid: 5613860